Search
HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech
He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector. Coverage brought to you by
2 days ago
H.C. Wainwright & Co.'s President of Capital Markets' Richard Gormley discusses the current environment for biotech
From the 2025 H.C. Wainwright Global Investor Conference, we discuss interest rates, M&A, data readouts, and more. Coverage brought to...
Sep 8, 2025
.png){kind=logo}